Citadel Advisors’s ASP Isotopes ASPI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.39M Sell
768,006
-957,547
-55% -$5.66M ﹤0.01% 5017
2025
Q4
$9.23M Buy
1,725,553
+559,788
+48% +$4.45M ﹤0.01% 3364
2025
Q3
$11.2M Buy
1,165,765
+1,020,562
+703% +$9.41M ﹤0.01% 3103
2025
Q2
$1.07M Buy
+145,203
New +$974K ﹤0.01% 6941
2024
Q2
Sell
-50,695
Closed -$209K 14208
2024
Q1
$209K Sell
50,695
-53,844
-52% -$166K ﹤0.01% 10224
2023
Q4
$187K Buy
+104,539
New +$153K ﹤0.01% 10049

Other funds holding ASPI

Citadel Advisors's ASPI Position: Q1 2026 in Review

Citadel Advisors reduced its ASP Isotopes (ASPI) stake by 55% in Q1 2026, selling an estimated $5.66M and leaving 768,006 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #5017.

Citadel Advisors first reported a position in ASPI in Q4 2023 and has held it in 6 quarters since. The position peaked at $11.2M in Q3 2025. 177 funds tracked by Wall St. Rank hold ASPI as of Q1 2026.

  • Citadel Advisors held 768,006 shares of ASP Isotopes worth $3.39M as of Q1 2026.
  • Citadel Advisors sold 957,547 ASP Isotopes shares in Q1 2026, an estimated $5.66M.
  • ASP Isotopes made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5017 holding.
  • Citadel Advisors first reported a position in ASP Isotopes in Q4 2023 and has held it in 6 quarters since.
  • Citadel Advisors's ASP Isotopes position peaked at $11.2M in Q3 2025.
  • 177 funds tracked by Wall St. Rank held ASP Isotopes as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.